XTalks

MARCH 18, 2024

The precision fermentation study highlights how genetically engineered microorganisms can inhibit the growth of foodborne pathogens. Words like “bioengineered” and “genetically modified” often provoke negative reactions. This not only extends the shelf life of foods but also ensures they are safer for consumption.

Genetic Engineering 52

Genetic Engineering Genetics Production Protein 52

FDA Law Blog

DECEMBER 8, 2022

labeling of major food allergens in bulk foods, dietary supplements, protein-free ingredients, and foods produced through genetic engineering); and. labeling of major food allergens in bulk foods, dietary supplements, protein-free ingredients, and foods produced through genetic engineering); and.

Genetic Engineering 59

Genetic Engineering Containment Cosmetics Protein 59

Drug Discovery World

FEBRUARY 3, 2023

One of these candidates is VSV-SUDV, developed and tested by scientists at NIH’s National Institute of Allergy and Infectious Diseases in Hamilton, Montana. In the current studies, the investigators replaced the key EBOV protein in Ervebo with the comparable protein from SUDV.

Vaccination 52

Vaccination Vaccine Genetic Engineering Protein 52

Roots Analysis

MARCH 16, 2023

It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Jonathan Fisher, PhD, Group Leader, University College London, on: ‘Local secretion of immune active proteins for direct and bystander tumour killing’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40